NLM Selects InTouch for Indexing in the MEDLARS System

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

WASHINGTON-InTouch magazine, published by PRR for cancer patients and their family members, has been selected by the US National Library of Medicine (NLM) to be indexed and included in Index Medicus and MEDLINE.

WASHINGTON—InTouch magazine, published by PRR for cancer patients and their family members, has been selected by the US National Library of Medicine (NLM) to be indexed and included in Index Medicus and MEDLINE.

"It’s a real tribute to the editorial quality of InTouch," Steven T. Rosen, MD, said. Dr. Rosen, director of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, serves as medical editor-in-chief for InTouch, which just celebrated its third year of publication.

The National Library of Medicine looks to an advisory committee—the Literature Selection Technical Review Committee—to choose journals and other publications for citation. Composed of authorities knowledgeable in the field of biomedicine, the committee includes physicians, researchers, educators, editors, health science librarians, and historians who review and recommend titles for indexing.

The databases in the MEDLARS system in which InTouch will appear are Index Medicus and its online counterpart, MEDLINE, the system’s principal online bibliographic citation database. About 4,500 titles are indexed and included in the MEDLINE database, and 3,630 in Index Medicus.

"We’re delighted that the NLM has recognized the integrity and value of the information in InTouch," Dr. Rosen said. "Their endorsement furthers our mission, which is to give patients and their loved ones the most authoritative and up-to-date information on cancer prevention and treatment so that they can be better informed about their health care."

To search MEDLINE, go to PubMed located on the web at www.ncbi.nih.gov/entrez/query.fcgi.  

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content